Phase I Clinical Trial for Advanced Colon and Pancreatic Cancer Opens in New York Using Rexin-G, the World's First Tumor-Targeted Gene Delivery Vector
Posted on: Tuesday, 5 April 2005, 06:00 CDT
LOS ANGELES, and NEW YORK, April 5 /PRNewswire/ -- Epeius Biotechnologies Corporation (http://www.epeiusbiotech.com/) announced today that a Phase I clinical trial has opened in New York to test the safety and efficacy of Rexin-G, the leading tumor-targeted gene delivery system (vector) developed for the treatment of metastatic colon and pancreatic cancer. In 2003, Rexin-G gained FDA approval as an Orphan Drug based on clinical demonstrations of the medical utility of Rexin-G as an effective treatment for pancreatic cancer. Six out of six initial patients with advanced pancreatic cancer responded favorably to Rexin-G, as evidenced by significant shrinkage and/or disappearance of metastatic tumor nodules, or stabilization of disease, relief from pain, weight gain and extension of over-all survival time, without experiencing the side effects generally associated with standard chemotherapy. Clinical trials of Rexin-G have now been expanded to include patients with colorectal cancer that has spread to the liver.
Epeius Biotechnologies Corporation recently secured exclusive licensing rights to its Pathotropic (disease-seeking) targeting platform, including the FDA-approved Targeted Delivery System (TDS) that enables its lead product, Rexin-G, to seek and destroy metastatic tumors. Following the success of "compassionate use" clinical trials using Rexin-G for metastatic pancreatic cancer, Epeius Biotechnologies has completed the transition from an academic start-up to a specialty pharmaceutical company, and has gained the financial support needed to expand the scope of its landmark clinical trials in the United States.
In a statement to the press, Dr. Frederick Hall, President and CEO of Epeius said that, "We are now in an excellent position to complete our mission: to develop our business plan in an exemplary manner, and to commercialize our high-value lead product for the benefit of cancer patients worldwide."
ABOUT EPEIUS:
Epeius Biotechnologies Corporation is a privately held biopharmaceutical company that was formed to develop and commercialize the first truly effective Targeted Delivery System (TDS) that can be injected directly into a vein to deliver genetic medicine preferentially to cancerous tumors that have spread throughout the body (metastatic cancer), without eliciting systemic side effects or organ damage.
More information: http://www.epeiusbiotech.com/.
This release was issued on behalf of the above organization by Send2Press(TM), a unit of Neotrope(R). http://www.send2press.com/
Epeius Biotechnologies Corporation
CONTACT: Dr. Frederick L. Hall, President and CEO, +1-818-771-7344, orfax, +1-818-243-7778, info@epeiusbiotech.com
Web site: http://www.send2press.com/
Web site: http:/// http://www.epeiusbiotech.com/
Source: PRNewswire
Related Articles
- Medicare Cuts Will Force Many Cancer Centers To Close, Stop Seeing Medicare Patients, Lay Off Staff, According To ASTRO Survey
- The World's Smallest Hero! Rexin-G, Targeted Therapy for Metastatic Cancers
- Drug That Targets Vasculature Growth Attacks Aggressive Thyroid Cancer, Mayo Clinic Researchers Report
- Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer
- Clinical Pharmacists Can Positively Contribute to Clinical Outcomes for HIV-Infected Patients
- Neurogen Commences Phase II Clinical Trial in Chronic Insomnia Patients
- Can-Fite Initiated Phase IIb Clinical Trials in Rheumatoid Arthritis Patients; Has Achieved Milestones Enabling It to Convert Issued Debentures
- Palatin Technologies and King Pharmaceuticals Complete Enrollment in Two Phase IIb Clinical Trials Evaluating Bremelanotide in Patients With Erectile Dysfunction
- Targeted Genetics Announces Preliminary Results of Phase I Clinical Trial of tgAAC94 in Patients With Inflammatory Arthritis
- Peregrine Pharmaceuticals Opens Patient Enrollment for Its Tarvacin(TM) Phase I Solid Cancer Therapy Clinical Trial
 |
 |
User Comments (0)
RSS Feeds